The Short Version
Clinical evidence strongly supports that red yeast rice preparations containing meaningful amounts of monacolin K lower LDL and total cholesterol in humans, with meta-analyses of randomized controlled trials showing 15–25% LDL reductions. However, the claim requires an important caveat: monacolin K content varies widely across commercial products, and in the U.S., products with substantial monacolin K face FDA restrictions as unapproved drugs. Not all retail red yeast rice supplements will reliably produce cholesterol-lowering effects.